Dietary supplementation with @entity7784 ( @entity8393 ) improves the prognosis of chronic inflammatory diseases, including @entity731 . The mechanism underlying these beneficial effects, however, remains to be elucidated. Here we show that @entity8393 protects endothelial cells from anoikis through upregulation of the cellular @entity8186 (Fas-associating protein with death domain-like interleukin-1-converting enzyme)-inhibitory protein (cFLIP), an endogenous inhibitor of @entity8186 . @entity8393 -induced upregulation of cFLIP expression was partially suppressed by the @entity4357 -3-kinase inhibitor @entity2307 . Conversely, treatment with @entity442 ( @entity442 ), an activator of @entity4357 -3-kinase/ @entity584 signaling, or infection with an adenoviral construct expressing the constitutively active @entity584 gene induced upregulation of cFLIP expression. In addition, pretreatment of endothelial cells with either @entity8393 or @entity442 protected them from anoikis, suggesting that @entity8393 -induced protection against anoikis is partially mediated through activation of @entity584 . On the other hand, when endothelial cells were already detached, treatment of these cells with @entity8393 but not with @entity442 protected them against anoikis. Importantly, @entity8393 restored cFLIP expression without activating @entity584 signaling in detached endothelial cells, whereas @entity442 had no effect. Additionally, exogenously restored expression of cFLIP by the @entity803 -regulated adenovirus system protected endothelial cells against anoikis. Furthermore, @entity8393 was protective against the loss of endothelium in an organ culture of @entity35 aortas. These findings suggest that @entity8393 protects against endothelial cell anoikis through restoration of cFLIP expression, which might contribute to the mechanism underlying the beneficial effects of @entity8393 in @entity1 with @entity101 .

XXXX protects endothelial cells against anoikis through restoration of cFLIP.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity7784 :: ('MESH:D015118', 'Chemical') :: ['eicosapentaenoic acid'] @entity8393 :: ('CHEBI:28364', 'Chemical') :: ['EPA'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension'] @entity442 :: ('3479', 'Gene') :: ['insulinlike growth factor-1', 'IGF-1'] @entity8186 :: ('841', 'Gene') :: ['caspase-8', 'FLICE'] @entity2307 :: ('MESH:C009687', 'Chemical') :: ['wortmannin'] @entity584 :: ('207', 'Gene') :: ['Akt'] @entity35 :: ('10116', 'Species') :: ['rat'] @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerosis'] @entity803 :: ('MESH:D013752', 'Chemical') :: ['tetracycline'] @entity4357 :: ('MESH:D010716', 'Chemical') :: ['phosphatidylinositol']
@entity7784 :: (MESH:D015118,Chemical) :: ['Eicosapentaenoic acid']
